Immunotherapy drug may extend remission in advanced esophageal cancer
NCT ID NCT07246330
First seen Nov 25, 2025 · Last updated Jun 07, 2026 · Updated 30 times
Summary
This phase 3 trial tests whether the immunotherapy drug toripalimab can help keep advanced esophageal cancer from growing after initial treatment. About 340 adults with unresectable esophageal squamous cell carcinoma who responded to chemo-immunotherapy and chemoradiation will either receive toripalimab or be observed. The goal is to see if toripalimab improves the time before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.